NeuroRestore’s success comes from fusing academia, hospital care and industry into one translational pipeline for spinal cord injury – a template other neurotech labs would do well to study.

In the age of artificial intelligence are MDs being taught enough to capitalise on this emerging technological potential?

BCIs are best understood as constrained medical technologies rather than general-purpose enhancement tools… at least for the foreseeable future.

As I found this year, successful Australian medtech startups follow three key pillars: being science-first, hiring interdisciplinary staff and and carefully balancing product breadth with depth.